ArticleFrontiers in oncology2026
Assessment of subventricular zone irradiation in glioblastoma patients.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with near-universal recurrence despite multimodality treatment. Increasing evidence suggests that the subventricular zone (SVZ), a major neural stem cell niche, may contribute to tumor aggressiveness, recurrence, and therapeutic resistance. However, the clinical significance of incidental SVZ irradiation remains controversial. Methods: This prospective analytical study included 28 consecutive patients with histologically confirmed GBM treated uniformly with maximal safe resection followed by temozolomide-based chemoradiation using IMRT/VMAT. Ipsilateral, contralateral, and bilateral SVZs were retrospectively contoured, and dosimetric parameters were extracted. Survival outcomes were correlated with SVZ contact and radiation dose. The primary endpoints were overall survival (OS) and progression-free survival (PFS). Results: With a median follow-up of 14.5 months, median OS and PFS were 13 months and 6.5 months, respectively. Tumors contacting the SVZ were associated with inferior OS (7 vs 15 months; p = 0.044) and shorter PFS. On univariate analysis, SVZ contact was associated with worse survival (HR 4.04). Among patients with SVZ-contacting tumors, a higher ipsilateral SVZ dose (≥52.14 Gy) showed a trend toward improved OS (p = 0.04). However, given the limited number of events, these findings should be interpreted with caution. Conclusion: SVZ contact appears to identify a higher-risk subgroup of GBM patients. Higher incidental irradiation of the ipsilateral SVZ may be associated with improved survival; however, due to the small sample size and limited events, these findings are exploratory and hypothesis-generating. Larger prospective studies are required before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.